Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00090649
NCT00090649
Completed
Phase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Of DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder

Wyeth is now a wholly owned subsidiary of Pfizer0 sites369 target enrollmentSeptember 1, 2004
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMajor Depressive Disorder
DrugsDVS-233 SR

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
369
Status
Completed
Last Updated
16 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

To compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.

Registry
clinicaltrials.gov
Start Date
September 1, 2004
End Date
March 2005
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • •Men and women 18 to 75 years of age, inclusive.
  • •Sexually active individuals participating in the study must use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article
  • •Subjects must have a primary diagnosis of major depressive disorder

Exclusion Criteria

  • •Treatment with DVS-233 SR at any time in the past
  • •Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1
  • •Known hypersensitivity to venlafaxine (IR or ER)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive DisorderMajor Depressive Disorder
NCT00087737Wyeth is now a wholly owned subsidiary of Pfizer369
Completed
Phase 3
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive Disorder
NCT00072774Wyeth is now a wholly owned subsidiary of Pfizer480
Completed
Phase 3
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive Disorder
NCT00073762Wyeth is now a wholly owned subsidiary of Pfizer375
Completed
Phase 3
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive DisorderMajor Depressive Disorder
NCT00063206Wyeth is now a wholly owned subsidiary of Pfizer247
Completed
Phase 3
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive DisorderDepressionDepressive DisorderMajor Depressive Disorder
NCT00092911Wyeth is now a wholly owned subsidiary of Pfizer244